

---

---

**UNITED STATES  
SECURITIES AND EXCHANGE COMMISSION**  
Washington, D.C. 20549

**FORM 8-K**

**CURRENT REPORT**

Pursuant to Section 13 OR 15(d) of The Securities Exchange Act of 1934

Date of Report (Date of earliest event reported): August 28, 2017

**IMPRIMIS PHARMACEUTICALS, INC.**

(Exact name of registrant as specified in its charter)

**Delaware**  
(State or other jurisdiction  
of incorporation)

**001-35814**  
(Commission  
File Number)

**45-0567010**  
(IRS Employer  
Identification No.)

**12264 El Camino Real, Suite 350**  
**San Diego, CA**  
(Address of principal executive offices)

**92130**  
(Zip Code)

Registrant's telephone number, including area code: **(858) 704-4040**

**N/A**

(Former name or former address if changed since last report.)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

- Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
  - Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
  - Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
  - Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
- 
- 
-

**Item 7.01. Regulation FD Disclosure**

Attached as Exhibit 99.1 and Exhibit 99.2 to this Item 7.01 is a presentation and materials that are being used by the management of Imprimis Pharmaceuticals, Inc. (the “Company”) in meetings describing the Company.

The information contained in Item 7.01 of this report and in Exhibit 99.1 and Exhibit 99.2 shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), or incorporated by reference in any filing under the Securities Act of 1933, as amended, or the Exchange Act, except as shall be expressly set forth by specific reference in such a filing.

**Item 9.01. Financial Statements and Exhibits****(d) Exhibits**

99.1 Presentation dated August 2017

99.2 Fact Sheet dated August 2017

---

**SIGNATURES**

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

**Imprimis Pharmaceuticals, Inc.**

Date: August 28, 2017

By: /s/ Andrew R. Boll

Name: Andrew R. Boll

Title: Chief Financial Officer

---



**NASDAQ: IMMY**

**August 2017**

## Safe Harbor

This presentation contains express “forward-looking statements” as defined in the Private Securities Litigation Reform Act of 1995. You are cautioned not to rely on these forward-looking statements. These statements are based on current expectations of future events. If underlying assumptions prove inaccurate or known or unknown risks or uncertainties materialize, actual results could vary materially from Imprimis Pharmaceuticals, Inc.’s (the “Company” or “Imprimis”) expectations and projections. Some of these risks and uncertainties include, but are not limited to: the Company’s ability to make commercially available its formulations and technologies in a timely manner or at all; market acceptance of the Company’s formulations and challenges related to the marketing of the Company’s formulations; its ability to obtain intellectual property protection for its assets; its ability to accurately estimate its expenses and cash burn and raise additional funds when necessary; its ability to generate profits from sales of its formulations; risks related to research and development activities; its estimates of the current and potential market size for its technologies and formulations; unexpected data, safety and technical issues; regulatory and market developments impacting compounding pharmacies, outsourcing facilities and the pharmaceutical industry; competition; and market conditions. More detailed information about the Company and the risk factors that may affect the realization of forward-looking statements is set forth in the Company’s filings with the Securities and Exchange Commission, including its Annual Reports on Form 10-K and its Quarterly Reports on Form 10-Q filed with the SEC. Such documents may be read free of charge on the SEC’s web site at [www.sec.gov](http://www.sec.gov). All forward-looking statements are qualified in their entirety by this cautionary statement. You are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date hereof. Imprimis expressly disclaims any intent or obligation to update these forward-looking statements except as required by law.



## Company Snapshot

- Pharmaceutical company focused on the three largest U.S. ophthalmic markets: Cataract, Glaucoma, Dry Eye
- 1,700+ ophthalmology customers & growing
- IP focused, 50+ patents and pending patent applications
- Cash-based 90% of revenues
- Not reliant on “middlemen” (PBMs, insurance, rebates, wholesalers)
- Solutions address market interest in affordable pharmaceutical innovation
- New ophthalmic formulations for infection/inflammation to expand market share



## Performance & Planned Growth


- 13 consecutive quarters of double digit y/y growth
- 245% revenue CAGR since ophthalmology product line launch (2014 - 2016)
- Ranked 4<sup>th</sup> fastest growing U.S. pharmaceutical/biotech and 12<sup>th</sup> overall on Deloitte’s 2016 Technology Fast 500™
- Estimated >10% share in post-cataract and refractive procedure care markets
- 2017 Expectations:
  - Scaling production drives COGS efficiency
  - Use 503B status to grow market share and increase margins to 50% to 60%
  - Realize operating profit (Adj. EBITDA)



## Other Assets and Businesses


- Non-Ophthalmology Business
  - Integrative Medicine and Urology
  - Focused on proprietary and niche formulations
  - 40% of 2016 fiscal year revenue
- Eton Pharmaceuticals
  - 505(b)(2) development company
  - Proprietary drug candidates for billion dollar market opportunities
  - Spun-out in June 2017; raised \$20M
  - Imprimis owns 27% equity stake
- Surface Pharmaceuticals
  - 505(b)(2) development company
  - Proprietary drug candidates focused on ocular surface diseases
  - May seek separate, outside financing similar to Eton
- IT Platform
  - Developing marketplace for drug manufacturers and purchasers

## Traditional Pharmaceutical Value Chain



## 100% Transparency

- No insurance company, pharmacy benefit manager (PBM), wholesaler or distributor middlemen
- No formulary rejections, discount cards or rebates
- No payment submittals, investigations or PBM clawbacks
- No need for “Patient Assistance Programs” with affordable pricing






# 2017 Expected Margin Expansion

## Production Efficiency



- FDA registered/inspected cGMP production facility in New Jersey opened in February 2017
- \$5M+ investment in equipment and automation
- Increased batch sizes and unit yields per batch
- Lower labor costs (fewer FTEs; lower-cost personnel)
- Orders shipped without patient Rx
- cGMP standards open new account opportunities


## Order & Fulfillment Efficiency



- “Amazon-like” online ordering and fulfillment portal bypasses customer service directly to fulfillment
- Automated invoice generation and labeling
- Minimum order requirement of 20 units increases average sales per order
- Improved customer convenience and satisfaction
- Reduced customer service costs per order

# Revenue Performance

(in thousands)



\* Does not include \$818 gain paid for business interruption insurance claim related to lost profits for down time of Texas facility.



# Ophthalmology Business



---

# Dropless Cataract Surgery®

## Dropless Therapy®



## Standard of Care



### What is it?

- Patent-pending one-time steroid/antibiotic combination injection at the end of cataract surgery
- Disrupting the \$1B+ eye drop market

### Why is it important?

- Substantially reduces or eliminates the need for post-operative eye drops
- Lower-cost compared to standard of care eye drops costing an estimated \$323<sup>1</sup>
- Patients and MDs prefer Dropless®<sup>2</sup>
- Over 500,000 units sold since mid-2014
- Strong body of supportive clinical research<sup>2-4</sup>

### What is the opportunity?

- Imprimis est. TAM = \$100M
- Growing market with aging population, 3.8M cataract surgeries annually in the U.S.<sup>5</sup>

# LessDrops® Combination Drop Therapy

LessDrops®



Standard of Care



**imprimis**  
PHARMACEUTICALS

## What is it?

- Patent-pending combination drop therapy used following cataract and refractive procedures:
  - Antibiotic + Steroid
  - NSAID + Steroid
  - Triple Drop®
- Disrupting the \$1B+ eye drop market

## Why is it important?

- Lower-cost compared to standard of care eye drops costing an estimated \$323<sup>1</sup>
- Up to 50% fewer eye drop applications
- Growing business with over 400,000 units sold since launch in early 2015

## What is the opportunity?

- Imprimis est. TAM = \$300M
- 3.8M cataract and 600,000 LASIK procedures annually in the U.S.<sup>5,6</sup>

## IV Free™ Conscious Sedation

MKO Melt®



Intravenous Sedation



### What is it?

- Patent-pending MKO Melt® sublingual sedation
- Combination midazolam, ketamine & ondansetron
- \$15 per Melt; sold in 1, 2 or 3 Melt packs

### Why is it important?

- Conscious sedation vs. intravenous sedation
- Growing customer base with over 150 prescribing MDs since launch in mid-2016





### What is the opportunity?

- Registering 503B with DEA (within next 12 months); should increase ease of ordering
- Imprimis est. ophthalmology TAM = \$100M
  - 4.4M ocular procedures performed annually in U.S.<sup>5,6</sup>
- Imprimis est. non-ophthalmology TAM = \$1.9B
  - 70M+ procedures\*<sup>7,8-18</sup>



\* Non-Ophthalmology markets include MRI procedures 34M<sup>8</sup>; dental procedures 20M<sup>9,10</sup>; colonoscopies 18M<sup>11</sup>; vasectomies 500,00<sup>12</sup>; biopsies 3.2M<sup>13-15</sup>; women's health 1.1M<sup>16,17</sup>; and cosmetic surgery procedures 500,000<sup>7,18</sup>.

# Imprimis Dropless® & MKO Melt® Experience For Cataract Surgery

|   | Before Imprimis   | Imprimis Solutions  |
|---|---|---|
|  <p>PRE-SURGERY</p> | <ul style="list-style-type: none"> <li>▪ MD prescribes patient with pre- and post-surgery drops</li> </ul>  | <ul style="list-style-type: none"> <li>▪ No pre- or post-surgery drops prescribed</li> </ul>  |
|  <p>SURGERY DAY</p> | <ul style="list-style-type: none"> <li>▪ Patient intravenously sedated, potentially anxious about needle</li> <li>▪ Potentially increased recovery time due to IV sedation</li> </ul>                               | <ul style="list-style-type: none"> <li>▪ Patient is given MKO Melt™ sublingually for sedation</li> <li>▪ Dropless Therapy® intravitreal injection is administered following cataract surgery</li> </ul> |
|  <p>POST-OP</p>     | <ul style="list-style-type: none"> <li>▪ Pharmacy switch Rx's</li> <li>▪ Potential confusion on drop regimen</li> <li>▪ Difficulty administering eye drops</li> <li>▪ Sometimes runs out with no refills</li> </ul> | <ul style="list-style-type: none"> <li>▪ Eye looks quiet</li> <li>▪ No infection</li> <li>▪ No inflammation</li> </ul>  |
|  <p>SUMMARY</p>    | <ul style="list-style-type: none"> <li>▪ Patient IV anxiety</li> <li>▪ Patient expense of &gt;\$300 for eye drops</li> <li>▪ Compliance concerns and calls to office staff</li> </ul>                               | <ul style="list-style-type: none"> <li>▪ No IV anxiety</li> <li>▪ Post-surgery drops eliminated or reduced</li> <li>▪ MD has no medication compliance concerns</li> </ul>                               |

# Simple Drops™ Glaucoma Eye Drops

## Simple Drops™



## Standard of Care is 2+ Bottles



### What is it?

- Simple Drops™ portfolio of combination drops for glaucoma launched in May of 2017
- Preservative-free, may reduce burning and stinging common in current drops
- Proprietary technology may increase corneal penetration and length of residence on the eye

### Why is it important?

- Glaucoma is chronic, incurable and, if not treated, can lead to blindness
- Lower-cost; more convenient than multiple drops

### What is the opportunity?

- Glaucoma is a \$2B drug market in the U.S.
- Imprimis est. TAM = \$500M+
- 4 million glaucoma patients in the U.S.<sup>19</sup>



# Dry Eye Disease Platform

## Chronic, non-surgical condition



## Proprietary formulations



### What is it?

- Patented Klarity™ platform for proprietary topical eye drop formulations
- Patent-pending oral formulation combining nutraceutical and antibiotic
- Launch in Q3 2017

### Why is it important?

- Dry Eye results from poor quality tears or lack of production, and can cause eye soreness, blurred vision, redness, feeling non existent particles

### What is the opportunity?

- Dry Eye is among the most common conditions seen by eye care professionals (20-30M Americans)
- 9-12M have moderate to severe Dry Eye
- Imprimis est. TAM = \$200M+

# Total Tears™ For Dry Eye Disease

## Customizable autologous formula



## Solutions for chronic patients



### What is it?

- Topical drops for Dry Eye Disease patients who do not respond to traditional treatments
- This customizable solution incorporates an individual's serum, found in their blood, which includes antibodies and growth factors
- Launched in Q3 2017

### Why is it important?

- Published data have demonstrated the benefits of using an individual's serum for the treatment of chronic Dry Eye Disease patients <sup>20-22</sup>

### What is the opportunity?

- May address moderate to severe Dry Eye Disease patients who do not respond to traditional treatments
- Imprimis est. TAM = \$50M+

## Ophthalmology Strategic Sales Partners



- Precision Lens sells and distributes ophthalmology focused devices - more than 60% market penetration with intraocular lenses (IOLs) in the markets they serve
- A dedicated sales team deploying Imprimis' entire ophthalmic portfolio to physicians in the Midwest



- SightLife Surgical is the world's largest eye bank, providing corneal tissue and medical devices for corneal transplant procedures
- Nationwide deployment of Imprimis Serum Tears to ophthalmic surgeons, large practice groups, hospitals, ASC's, healthcare organizations



## Other Markets & Businesses

---

# Eton Pharmaceuticals

## 505(b)(2) Spin-Out



p h a r m a c e u t i c a l s

## Billion Dollar Market Opportunities



### What is it?

- 505(b)(2) focused development stage company
- Spun-out of Imprimis June 2017 (\$20M Series A)
- Funded and managed separately from Imprimis

### Why is it important?

- Imprimis holds passive 27% equity stake in Eton
- 6% royalty on sales of Imprimis contributed patent-pending drug candidates
- Allows Imprimis to focus on its ophthalmology centered business strategy

### What is the opportunity?

- Synthetic Corticotropin: \$1.1B in annual sales for drug incumbent: H.P. Acthar<sup>®</sup> Gel (infantile spasms and MS relapse)
- Injectable Pentoxifylline: \$1B in drug market potential, drug incumbent: Xiaflex<sup>®</sup> (Peyronie's Disease)
- DESI assets may provide near term cash flow

# Surface Pharmaceuticals



## What is it?


- 505(b)(2) development stage company focused on ocular surface disease patented therapeutics
- Targeted spin-out within the next 12 months
- Will be funded and managed separately from Imprimis

## Why is it important?

- Transaction architecture likely similar to Eton Pharma; Imprimis will maintain large equity position and royalties on contributed drug candidates
- Allows Imprimis to focus on its commercialization strategy and achieve highest and best use for assets

## What is the opportunity?

- Patent-pending eye drop formulations for chronic and episodic Dry Eye patients; drug incumbent: Restasis® (\$1.5B, 2016 sales)
- Patent-pending oral capsule for non-responders to traditional Dry Eye remedies; and potentially Blepharitis patients



# Integrative Medicine

Ascorbic Acid,  
Curcumin & Artesunate



24% of total 2016 revenues



## What is it?

- Integrative medicines for oncology, autoimmune diseases and chronic infectious diseases
- Leading medications include ascorbic acid (non-corn source), Vitamin B-complex, and artesunate (lyophilized)

## Why is it important?

- Integrative medicines represented 24% of total 2016 revenues
- Customers are thought leaders in their fields
- Imprimis' leadership demonstrated by Integrative Therapies Institute (ITI) educational conferences (running since 2012)

## What is the opportunity?

- Imprimis est. TAM = \$100M

# Injectable For Erectile Dysfunction

## Tri-Mix Injectable



### What is it?

- Tri-Mix (phentolamine, papaverine and prostaglandin) injectable for erectile dysfunction (ED)

### Why is it important?

- Recommended treatment by the American Urology Association (AUA)
- Lower-cost vs. standard of care oral medications
- Growing business with over 450,000 doses dispensed
- Key customer is a leading national managed healthcare company

## Recommended by AUA



### What is the opportunity?

- Imprimis est. TAM = \$500M+
- 30M U.S. males have ED<sup>23</sup>





# Summary

---

# imprimis<sub>Rx</sub> Value Proposition

## Ophthalmology Focused

Commercial products in the 3 largest U.S. ophthalmic drug markets

- Cataract \$1B
- Glaucoma \$2B
- Dry Eye \$2B

## Products and Market Share

- IP focused; 50+ patents or pending patents (US & Int'l) for our formulations
- Consistent growth in ophthalmology market share
- Products offer unique value propositions at lower costs; significant investments in quality
- Over 1,700 customers and growing

## Growth & Profitability

- Strong revenue growth expected in 2017
- Management team focused on near term profitability and continued growth
- FDA registered cGMP 503B facility opens new account opportunities

## 505(b)(2) Assets

Equity ownership stake and royalty interest in two 505(b)(2) drug development firms

- Eton Pharma \$2B drug sales potential
- Surface Pharma \$2B drug sales potential

# Company Profile



Trading symbol: **NASDAQ: IMMY**

Price per share (8-1-2017): **\$2.50**

Stock price range (52-week): **\$1.65 - \$4.69**

Avg. daily Q2 trading volume: **216,000 shares**

Market cap: **\$50 million**

Shares Outstanding: **20.1 million**

Insider Beneficial Ownership: **13%\***

\*Recent additions by CEO, CFO, Director from participation in December 2016 financing

Corporate headquarters: **San Diego, CA**

Facilities: **Irvine, CA & Ledgewood, NJ**

Website: **[www.ImprimisRx.com](http://www.ImprimisRx.com)**





## References and Appendix



---


# References

1. Andrew Chang & Co LLC. Analysis of the Economic Impacts of Dropless Cataract Therapy on Medicare, Medicaid, State Governments, and Patient Costs (2015, October). Retrieved January 5, 2016, from [http://www.improvedeyecare.org/CSIE\\_Dropless\\_Economic\\_Study.pdf](http://www.improvedeyecare.org/CSIE_Dropless_Economic_Study.pdf)
2. Fisher, B. L., & Potvin, R. (2016, July 18). Transzonular vitreous injection vs a single drop compounded topical pharmaceutical regimen after cataract surgery. Retrieved October 18, 2016, from <https://www.dovepress.com/transzonular-vitreous-injection-vs-a-single-drop-compounded-topical-ph-peer-reviewed-fulltext-article-OPHTH>
3. Tyson, S. L., et al. (2016, September 30). Clinical outcomes after injection of a compounded pharmaceutical for prophylaxis after cataract surgery: A large-scale review. Retrieved November 5, 2016, from [http://journals.lww.com/co-ophthalmology/Abstract/publishahead/Clinical\\_outcomes\\_after\\_injection\\_of\\_a\\_compounded.99409.aspx](http://journals.lww.com/co-ophthalmology/Abstract/publishahead/Clinical_outcomes_after_injection_of_a_compounded.99409.aspx)
4. Lindstrom, R.L., et al. (2017). Dropless Cataract Surgery: An Overview. *Clinical Ophthalmology*. (E-pub ahead of print – Volume 22) from <http://benthamscience.com/journals/current-pharmaceutical-design/article/147752/>
5. Market Scope, LLC, Comprehensive Report on the Global IOL Market (2013, May).
6. Number of LASIK surgeries in the United States from 1996 to 2020. Retrieved February 9, 2016 from <https://www.statista.com/statistics/271478/number-of-lasik-surgeries-in-the-us/>
7. Imprimis Pharmaceuticals internal business data, 2015-2017
8. IMV Medical Information Division, Inc. Benchmark Report MR2013 (2013, July). Retrieved December 15, 2016.
9. Endodontic Facts by the American Association of Endodontists. (n.d.). Retrieved January 07, 2017, from <http://www.aae.org/about-aae/news-room/endodontic-facts.aspx>
10. Friedman, J. W. (2007, September). The Prophylactic Extraction of Third Molars: A Public Health Hazard. Retrieved January 08, 2017, from <https://www.ncbi.nlm.nih.gov/pmc/articles/PMC1963310/>
11. US Market Report Suite for Gastrointestinal Endoscopic Devices 2017 - MedSuite. (2016, August 01). Retrieved January 08, 2017, from <https://www.idataresearch.com/product/us-market-report-suite-for-gastrointestinal-endoscopic-devices-2017-medsuite/>
12. Allen, A. (2007). Vasectomy Risks and Benefits. Retrieved November 08, 2016, from <http://www.webmd.com/men/features/vasectomy-risks-benefits>
13. Elmore, J. G., MD, Longton, G. M., MS, & Carney, P. A., PhD. (2015, March 17). Diagnostic Concordance in Interpreting Breast Biopsies. Retrieved January 08, 2017, from <http://jamanetwork.com/journals/jama/fullarticle/2203798>
14. Voigt, J., & Mosier, M. (2013, September). A powered bone marrow biopsy system versus manual methods: a systematic review and meta-analysis of randomised trials. Retrieved January 08, 2017, from <https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3756462/>

# References

15. Irwin, K. (2012, December 10). Prostate cancer now detectable using imaging-guided biopsy, UCLA study shows. Retrieved January 08, 2017, from <http://newsroom.ucla.edu/releases/prostate-cancer-now-detectable-241575>
16. Sklavos, M. M., Spracklen, C. N., Saftlas, A. F., & Pinto, L. A. (2014, February 23). Does Loop Electrosurgical Excision Procedure of the Uterine Cervix Affect Anti-Müllerian Hormone Levels? Retrieved January 08, 2017, from <https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3953513/>
17. Centers for Disease Control and Prevention - United States. (2016, November 24). Retrieved January 07, 2017, from <https://www.cdc.gov/mmwr/volumes/65/ss/ss6512a1.htm>
18. ASPS 2015 Plastic Surgery Statistics Report - American Society of Plastic Surgeons. (2015). Retrieved January 8, 2017, from <https://d2wirczt3b6wjm.cloudfront.net/News/Statistics/2015/plastic-surgery-statistics-full-report-2015.pdf>
19. Glaucoma Research Foundation. Glaucoma Facts and Stats. Retrieved February 9, 2017 from <http://www.glaucoma.org/glaucoma/facts-statistics/glaucoma-facts-and-stats.php>
20. Noda-Tsuruya, T., Asano-Kato, N., Toda, I., & Tsubota, K. Autologous serum eye drops for dry eye after LASIK. *J Refract Surg.* 2006 Jan-Feb;22(1):61-6. Retrieved April 29, 2017, from <https://www.ncbi.nlm.nih.gov/pubmed/16447938>
21. Kojima, T., Ishida, R., Dogru, M., Goto, E., Matsumoto, Y., Kaido, M., & Tsubota, K. (2005, February). The effect of autologous serum eyedrops in the treatment of severe dry eye disease: a prospective randomized case-control study. *Am J Ophthalmol.* 2005 Feb;139(2):242-6. Retrieved April 29, 2017, from <https://www.ncbi.nlm.nih.gov/pubmed/15733983>
22. Mondy, P., Brama, T., Fisher, J., Gemelli, C. N., Chee, K., Keegan, A., & Waller, D. (2015, December). Sustained benefits of autologous serum eye drops on self-reported ocular symptoms and vision-related quality of life in Australian patients with dry eye and corneal epithelial defects. *Transfus Apher Sci.* 2015 Dec;53(3):404-11. doi: 10.1016/j.transci.2015.11.011. Epub 2015 Nov 25. Retrieved April 29, 2017, from <https://www.ncbi.nlm.nih.gov/pubmed/26626963>
23. National Institute of Diabetes and Digestive and Kidney Diseases. Erectile Dysfunction. Retrieved February 9, 2017 from <https://www.niddk.nih.gov/health-information/urologic-diseases/erectile-dysfunction>

## Drug Combination IP



## Published Clinical Data

**Tyson, S. L., et al. (2017, January). Clinical outcomes after injection of a compounded pharmaceutical for prophylaxis after cataract surgery: a large-scale review. *Current Opinion in Ophthalmology*.**

No major intraoperative complications associated with the transzonular injection technique. There were no cases of postoperative endophthalmitis. Rates of infection and inflammation reported in this retrospective review of 1,541 cases from 922 patients receiving a transzonular injection of Tri-Moxi-Vanc for prophylaxis after cataract surgery appear similar to reported rates with alternative prophylactic therapies such as topical drops.<sup>5</sup>

**Fisher, B. L., & Potvin, R, (2016, July 18). Transzonular vitreous injection vs a single drop compounded topical pharmaceutical regimen after cataract surgery. *Current Pharmaceutical Design*.**

Review of the rationale for reducing topical therapy in cataract surgery prophylaxis, and what is known to date about the efficacy and safety of the Dropless® approach. Both groups expressed similar satisfaction with surgery, but patients who received Dropless® preferred the overall experience ( $P=0.01$ ).<sup>4</sup>

**Lindstrom, R.L., et al. (2017, February). Dropless Cataract Surgery: An Overview. *Current Pharmaceutical Design*.**

Compliance issues are diminished with Dropless Therapy compared to standard post-surgery topical drop regimens. Cost savings to patients can range from \$200 to \$600 per cataract procedure. Staff time is reduced without patient, insurance and pharmacy callbacks about eye drop substitutions and confusion over topical regimens. A retrospective review of Dropless Therapy cases found no postoperative endophthalmitis. Post- surgery infection and inflammation rates were similar to reported rates with other alternative prophylactic therapies, such as topical drops.<sup>6</sup>





**Imprimis Pharmaceuticals  
(NASDAQ: IMMY)**

12264 El Camino Real, #350  
San Diego, CA 92130  
(858) 704-4040

[ir@imprimispharma.com](mailto:ir@imprimispharma.com)  
[www.imprimispharma.com](http://www.imprimispharma.com)



## Investment Highlights

**Ophthalmology-focused pharmaceutical company with commercial products in the three largest U.S. ophthalmic markets**

13 consecutive quarters of double digit or better year over year revenue growth

Q2-2017 Net Income: \$1.5M

Gross margins increased each fiscal year:

- 2014: 34%
- 2015: 46%
- 2016: 51%

2017 goals: Establish operating profits (Adj. EBITDA) and increase gross margins to 60%

13% insider ownership

- Recent additions by CEO, CFO, Director from participation in December 2016 financing

50+ patents and pending patents (US & International) for our formulations

27% ownership in Eton Pharmaceuticals

- 505(b)(2) development co.
- Synthetic Corticotropin (Incumbent: Acthar® Gel)
- Injectable Pentoxifylline (Incumbent: Xiaflex®)

1,700+ ophthalmologist customers and growing

FDA registered / inspected cGMP production facility opened in February 2017


New business lines launched in 2H 2017 within Glaucoma and Dry Eye Disease

## Financial Snapshot

Trading Symbol: NASDAQ: IMMY  
Price per Share: \$2.50 (Aug. 1, '17)

Market Cap: \$50 Million  
Shares Outstanding: 20.1 Million


Avg. daily 2Q volume: 216,000 shares  
52-week price range: \$1.65 - \$4.69



|  | Cataract / LASIK   | Glaucoma  | Dry Eye Disease   |
|--|--|---|---|
| <b>How many people are estimated to be affected?</b> | 4.4M procedures in the US performed annually   | 4M Americans have Glaucoma  | 20-30M Americans suffer from Dry Eye  |
| <b>Market size</b>                                   | \$1B+  | \$2B+   | \$2B+   |
| <b>Imprimis' TAM</b>                                 | \$500M (aggregate)   | \$500M  | \$500M  |
| <b>Market challenges</b>                             | Eye drops are a nuisance post-procedure  | Poor compliance leads to preventable blindness  | Non-surgical; requires multiple "tools" to treat  |
| <b>Our unique value proposition and solutions</b>    | Injectable and combination eye drops to eliminate or reduce need for topical drops. Allows for better compliance, lower costs, and fewer patient callbacks to MD | Combination eye drops may increase patient compliance, decrease cost, and are preservative-free, which may reduce burning associated with other eye drops | Platform solution of topical eye drops and oral for individuals who do not respond to traditional treatments (estimated 70% patients) |
| <b>Patented or patent-pending offerings</b>          | Dropless Therapy®<br>LessDrops®<br>MKO Melt®   | Simple Drops®   | Klarity™<br>Total Tears™<br>OmegaDoxy™  |

## Cataract / LASIK — Since 2014

Cost, call back and compliance are some of the most common complaints for post-cataract and LASIK procedure care. By utilizing SSP Technology, our patent-pending Dropless and LessDrops formulations address these issues.



Dropless Therapy compounded antibiotic and steroid formulations are available in single, injectable intraocular doses administered by physicians following cataract surgery. Dropless

Therapy may substantially reduce or eliminate the need for patient-administered eye drops following surgery, thereby largely eliminating patient non-compliance and dosing errors associated with post-operative care regimens. Dropless has been dispensed over 500,000 times.



LessDrops combination topical eye drops may reduce the need for multiple post-operative eye drops following cataract, LASIK and other ocular procedures. This approach may help

to cut medication costs, improve compliance and enhance the patient experience. It is estimated that LessDrops combination topical drops can require up to 50% fewer drops to be administered by patients and cost up to 75% less than current post-procedure eye drop regimens. LessDrops has been dispensed over 400,000 times.



IV Free MKO Melt (midazolam, ketamine and ondansetron) compounded conscious sedation formulation is an alternative to IV anesthesia for patients undergoing ocular or any other surgical procedure. The MKO Melt, in troche (lozenge) format, may provide consistent predictable dosing and allow for quick and easy administration, resulting in better experiences for patients and staff. Since its launch in mid-2016, the customer base grown quickly, with over 150 prescribing physicians.

## Glaucoma — Launched Q3-2017

Glaucoma is a chronic, incurable, disease which damages the optic nerve and, if not treated, can lead to blindness.



Simple Drops are proprietary preservative-free combination eye drops for patients suffering from Glaucoma. Our formulations

may improve compliance by reducing the number of drops patients need to administer daily and simplifying their dosage regimen. Simple Drops was launched in May of 2017 and sales of our formulations will begin impacting revenue in Q3-2017.

Source material referenced is available by contacting the company.

Other than drugs compounded at a registered outsourcing facility, all Imprimis compounded formulations may only be prescribed pursuant to a physician prescription for an individually identified patient consistent with federal and state laws.

Certain statements contained in this material contains forward-looking statements within the meaning of the U.S. Private Securities Litigation Reform Act of 1995. Any statements in this release that are not historical facts may be considered such "forward looking statements." Forward looking statements are based on management's current expectations and are subject to risks and uncertainties which may cause results to differ materially and adversely from the statements contained herein. These and additional risks and uncertainties are more fully described in Imprimis' filings with the Securities and Exchange Commission ([www.sec.gov](http://www.sec.gov)), including its Annual Report on Form 10-K and its Quarterly Reports on Form 10-Q. Except as required by law, Imprimis undertakes no obligation to update any forward-looking statements to reflect new information, events or circumstances after the date they are made, or to reflect the occurrence of unanticipated events.

## Dry Eye Disease — Launched Q3-2017

Dry Eye results from poor quality tears or lack of tear production, and can cause eye soreness, blurred vision, redness, and feeling particles in the eye when there are none.

Klarity is a patented topical solution and gel technology designed to protect and rehabilitate the ocular surface following ophthalmic procedures, contact lens wear, or in patients with moderate to severe DED. Our solution is preservative-free and can be formulated to any viscosity. Other drops do not treat the associated edema, free radical formation or have an agent like Chondroitin Sulfate, which can serve as a cell membrane stabilizer.



Total Tears are topical drops for moderate to severe Dry Eye patients who do not respond to traditional treatments. This customizable solution incorporates an individual's serum, found in their blood, which includes antibodies and growth factors. Published data have demonstrated the benefits of using an individual's serum for the treatment of chronic Dry Eye Disease patients.

OmegaDoxy is a patent-pending oral capsule combining omega-3 fatty acids and doxycycline. Studies have shown that consumption of antibiotics and omega-3 fatty acids may improve symptoms associated with DED. In an evaluation of 31 patients taking our OmegaDoxy formulation, and who were not responding to traditional DED treatments, 29 reported improvement in their DED signs and symptoms after 30 to 60 days.

## Other Businesses & Assets



Eton is a spin-off of Imprimis. It is a separately managed and financed entity which will develop and, if approved, commercialize two patent-pending sterile drug candidates in a \$2B+ annual combined drug market potential. Imprimis holds a 27% equity stake with royalty interest in the drug candidates. In June 2017, Eton raised \$20M in a Series A Round and announced CEO Sean Brynjelsen will lead the company.



Surface is an Imprimis subsidiary that focuses on ocular surface diseases, including the multi-billion dollar market for Dry Eye Disease (DED).

Similar to Eton, Imprimis is pursuing an opportunity to separately finance Surface to allow it to develop proprietary topical and oral 505(b)(2) drug candidates. Surface will be targeting the high percentage of patients who do not respond to current FDA-approved topical prescription DED products. Imprimis plans to retain an equity position in Surface and a royalty on commercial sales of certain Surface drug candidates.

## Corporate Information

### Leadership

Mark L. Baum, Founder/CEO

Andrew R. Boll, CFO

John P. Saharek, CCO

### IR Contact

Imprimis Pharmaceuticals

T: 858.704.4587

E: [ir@imprimispharma.com](mailto:ir@imprimispharma.com)

[www.ImprimisRx.com](http://www.ImprimisRx.com)

